Republic of Iraq Ministry of Higher Education and Scientific Research University of Diyala College of Veterinary Medicine Department of Microbiology



# ANTIMICROBIAL POTENTIAL OF PROBIOTIC LACTIC ACID BACTERIA ISOLATED FROM MILK OF LACTATING COW AGAINST THE MOST CONTAMINATED BACTERIAL INFECTION OF BURNS IN HUMAN

### A Thesis

Submitted to the Council of the College of Veterinary Medicine/ University of Diyala in a Partial Fulfillment of the Requirements for the Degree of Master of Science in Veterinary Medicine (Veterinary Microbiology)

### By

**Rawan Raad Hussein** 

# Supervised by

Asst. Prof. Ammar Riyadh Qasem Algburi (Ph.D)

October/2022

IRAQ

Rabi' al-Awal/1444

# مسم الله الرحمن الرحيم

# انَرْفَحُ حَرَجَاتِمٍ مَنْ نَشَاءُ وَفَوْقَ كُلَّ خِي عِلْمِ عَلَيْهُ"

حدق الله العظيم

سورة يوسف الآية٦٧

# **Supervisor Certification**

I certify that this thesis entitled (Antimicrobial Potential of Probiotic Lactic Acid Bacteria Isolated from Milk of Lactating Cow Against the most Contaminated Bacterial Infection of Burns in Human) was prepared by (Rawan Raad Hussein) under our supervision at the Department of Microbiology, College of Veterinary Medicine, University of Diyala, as a partial fulfillment of the requirements for the Master Degree of Science in Veterinary Medicine (Veterinary Microbiology).

#### Asst. Prof. Dr.

#### Ammar Riyadh Qasem Algburi

Department of Biotechnology College of Science University of Diyala 2022/ /

In view of the valuable recommendation, we forward this thesis for debate by the examining committee

#### Assist. Prof. Dr. Khalid Ibrahim Abd ALKhazraji

Vice Dean of Postgraduate Studies and Science Affairs College of Veterinary Medicine University of Diyala 2022/ /

#### **Examination Committee Certification**

We, the examination committee, certify that the entitled thesis (Antimicrobial Potential of Probiotic Lactic Acid Bacteria Isolated From Milk of Lactating Cow Against The Most Contaminated Bacterial Infection of Burns in Human) has been examined and read through all of its contents and related topics. The committee recommends that the student passed and awarded the degree of Master of Science in Veterinary Medicine (Veterinary Microbiology).

#### Prof. Dr.

#### Ali Ibrahim Ali Al-Ezzy

#### (Chairman)

2022/ /

Assist.Prof.Dr Hayfaa Mahmood Fahad

(Member)

2022/ /

Assist. Prof. Dr Zainab Hussein Mahdi (Member) 2022/ /

Asst. Prof. Dr

# Ammar Riyadh Qasem Algburi

#### (Member and Supervisore)

2022/ /

#### Prof. Dr.

#### Amer Khazaal Salih Al-Azzawi

Head of department of Microbiology

2022/ /

#### Assist. Prof. Dr.

#### Khalid Ibrahim Abd ALKhazraji

Dean of College of Veterinary Medicine

University of Diyala

2022/ /

# Dedication

I would like to dedicate this work to the one who encouraged me to persevere throughout my life, to the first and most prominent man in my life (*my dear father*), to the one with whom I rise, and on whom I rest, the giving heart (*my dear, affectionate mother*), to those who made an effort to help me in every step of my life (*my dear brothers*).



# Acknowledgements

# I would like to thank my supervisor, Dr. Ammar Riyadh Qasem Algburi

who was more than generous with his expertise and valuable time. His excitement and willingness to provide feedback made completing of this research an enjoyable experience. Special thanks to laboratory of the Burns Hospital for helping me in taking samples, as well as the People working in microbiology laboratory (Mr. Bashar and Mrs. Um Maher) in Ghazi al-Hariri Surgical Specialties Hospital in Baghdad. Special thanks to my colleagues (Postgraduate students) in our college for their support. Finally, I would like to thank all the faculty who taught me during the coursework in the first year of my master's study.



#### ABSTRACT

Burns infection is one of the most common consequences and the leading causes of death. The burn sites are particularly exposed to various infections, mostly, with bacteria that are resistant to many types of antibiotics, leading to a prolonged hospitalization, and invasive care procedures. Therefore, it is necessary to find alternative solutions to control burns infections. This study aimed to assessment antimicrobial potential of lactobacilli Cell Free Supernatants (CFS) and evaluation of their antimicrobial activity when combined with some antibiotics against the most isolated burn-contaminants bacteria. Regarding methodology, A 42 samples of cow's milk was collected from two different areas in Baghdad. Milk samples were inoculated onto MRS agar under aerobic conditions for 24 hrs at 37 ° C. The bacterial isolates in this study were identify using manual and automated (VITEK2 system). The most isolated *Lactobacilli* species were *Lactobacillus plantarum* (spp.1, spp.2, spp.3) and Lactobacillus acidophilus. Moreover, 187 swabs were collected from patients with burns infection living in Baghdad. Each of the burn swabs were inoculated onto enriched and selective culture media. The data indicated that *Pseudomonas aeruginosa* (34.22%) and *Staphylococcus aureus* (27.27%) were the most predominant isolates, followed by Acinetobacter baumannii (17.11%), Klebsiella pneumoniae (14.44%), Escherichia coli (4.81%) and Proteus *mirabilis*. (1.07%). These isolates were multi-drugs resistant (MDR). However, some bacterial contaminants were sensitive to certain antibiotics. A. baumannii

was sensitive to Minocycline and Colistin with MIC ( $\leq 1$ ) and ( $\leq 0.5$ ), respectively, *P. aeruginosa* was sensitive only to Colistin with MIC ( $\leq 0.5$ ), *S.* aureus was sensitive to Linezolid, Teicoplanin, Vancomycin, Tigecycline and Nitrofurantoin with MIC (<= 0.5), (<= 0.5), (<= 0.5), (<= 0.12) and (<= 16), respectively. This study reported that when CFS was combined with the used antibiotics, the zone of inhibition increased in some antimicrobial combinations compared to using antibiotics alone. The zones of P. aeruginosa growth inhibition were increased when CFS of L. plantarum spp. 1, L. plantarum spp. 2, L. plantarum spp. 3 and L. acidophilus were combined with Azithromycin, the zone of inhibition increase from zero to 27.5 mm, 25.5 mm, 24.5 mm and 22.5 mm, respectively. In most cases, a high zone of bacterial growth inhibition was noticed when CFS used alone. This study data showed that the highest auto-aggregation percentages were after 24 hrs of incubation, 87.2% for L. plantarum spp 2. The highest co-aggregation percentages were also reported after 24 hrs incubation between L. plantarum spp.2 and P. aeruginosa (88.4%). Furthermore, the minimum inhibitory concentration (MIC90) of CFS prepared from L. plantarum spp. 2 against P. aeruginosa was 50%, inhibited 97.17%. While the MIC90 of L. plantarum spp.3 CFS was 50% against A. baumanni, P. aeruginosa, K. pneumoniae, and S. aureus; prevened 99.92%, 99.87%, 99.85% and 99.55%, respectively of the their growth, p-value (< 0.05), and p-value (<0.001). No MIC90 were determined for L. plantarum spp. 1 and L. acidophilus' CFS against isolated bacteria. In addition, the Minimum Biofilm Inhibitory

Concentration (MBIC50) of lactobacilli CFS was detected in rang (25%-6.25%). The MBIC50 of CFS prepared from L. acidophilus against A. baumanni P. aeruginosa, K. pneumonia and S. aureus was ranged between 12.5% - 25%, preventing bacterial biofilm by 74.29%, 60.35%, 50.00% and 61.53%, respectively. While the MBIC50 of CFS prepared from L. plantarum spp. 1 were 12.5%, 6.25%, 12.5% and 25% which, prevented 67.14%, 62.92%, 63.04% and 67.91%, respectively of A. baumanni P. aeruginosa, K. pneumonia and S. aureus biofilm. In regards to the MBIC50 of CFS prepared from L. plantarum spp. 2, it was 12.5%, 6.25%, 12.5% and 25% inhibited 71.36%, 72.89%, 53.12% and 58.59%, of biofilm of A. baumanni P. aeruginosa, K. pneumonia and S. aureus, respectively. The MBIC50 of CFS prepared from L. plantarum spp. 3 against A. baumanni P. aeruginosa, K. pneumonia and S. aureus were; 25%, 12.5%, 6.25% and 25%, preventing 74.19%, 64.58%, 53.01% and 99.65% of the bacterial growth, respectively. The author concluded that Lactobacilli, alone, or in combination with some antibiotics could be used as effective-alternatives in the therapeutic applications to control burns bacteria. infection-associated pathogenic

III

## List of content

| Series  | Title  | Page |
|---------|--|------|
|         | Abstract   | Ι    |
|         | List of Contents   | IV   |
|         | List of Tables   | VI   |
|         | List of Figures and Pictures                                     | VIII |
|         | List of Abbreviations  | IX   |
| 1.1     | Introduction   | 2    |
| 1.2     | Objectives of the Study  | 6    |
| 2       | Literatures Review   | 7    |
| 2.1     | Anatomy and Physiology of the skin                               | 8    |
| 2.2     | Burns Infection  | 10   |
| 2.3     | Bacterial Burn Infection   | 12   |
| 2.3.1   | Staphylococcus Aureus  | 13   |
| 2.3.2   | Pseudomonas Aeruginosa   | 14   |
| 2.3.3   | Acinetobacter Baumannii  | 14   |
| 2.3.4   | klebsiella Pneumonia   | 15   |
| 2.4     | Antimicrobial Resistance (AMR)                                   | 15   |
| 2.5     | Pathogenesis of Burn infection                                   | 18   |
| 2.6     | Epidemiology of Burns  | 19   |
| 2.7     | Control of Burn Infection  | 20   |
| 2.8     | Antibiotic History and its Failure to Treat Bacterial Infections | 21   |
| 2.9     | Alternative Therapy  | 23   |
| 2.10    | Lactic Acid Bacteria as a Probiotic                              | 24   |
| 2.11    | Antimicrobial Combination to Control Bacterial Infections        | 27   |
| 3       | Material and Methods   | 29   |
| 3.1.1   | Instruments and Tools  | 30   |
| 3.2.1   | Antibiotics  | 31   |
| 3.1.3   | Culture media  | 32   |
| 3.1.3.1 | Preparation of Culture Media                                     | 32   |
| 1       | MacConkey Agar (MAC)   | 32   |
| 2       | Brain Heart Infusion Broth (BHI)                                 | 32   |
| 3       | Mueller Hinton Agar (MHA): (Kirby and Bauer, 1966)               | 32   |
| 4       | De man, Rogosa and Sharpe Broth (MRS broth)                      | 33   |
| 5       | Mannitol Salt Agar   | 33   |
| 3.1.4   | Solutions  | 34   |
| 3.1.4.1 | Phosphate Buffer Solution  | 34   |
| 3.1.5   | Sterilization  | 34   |
| 3.1.5.1 | Moist Heat Sterilization   | 34   |
| 3.1.5.2 | Dry Heat Sterilization   | 34   |
| 3.1.5.3 | Filtration (Membrane Sterilization)                              | 35   |
| 3.1.6   | Chemicals  | 35   |
| 3.2     | Biochemical Test   | 35   |
| 3.2.1   | Initial Biochemical Test   | 35   |
| 1       | Catalase Test  | 35   |

| 2     | Oxidase Test   | 36  |
|-------|--|-----|
| 3     | Triple Sugar Iron (TSI)  | 36  |
| 4     | Citrate Utilization Test (Simmon Citrate)  | 36  |
| 5     | Indole Production Test   | 37  |
| 6     | Arginine Hydrolysis Test   | 37  |
| 7     | Esculine Hydrolysis Test   | 37  |
| 3.2.2 | Automatic Method to Confirm Bacterial Species Identification   | 38  |
| 3.3   | Lactic Acid Bacteria (LAB)   | 38  |
| 3.3.1 | Sample Collection  | 38  |
| 3.3.2 | Isolation of Lactic Acid Bacteria (LAB)  | 38  |
| 3.3.3 | Identification of Lactic Acid Bacteria (LAB)   | 39  |
| 3.4   | Pathogenic Bacteria from Burns Infections  | 39  |
| 3.4.1 | Samples Collection   | 39  |
| 3.4.2 | Samples Culturing  | 39  |
| 3.4.3 | Identification of Pathogenic Bacteria  | 40  |
| 3.5   | Auto-aggregation and Co-aggregation  | 40  |
| 3.6   | Antibiotic Sensitivity Test  | 41  |
| 3.7   | Determination of the Minimum Inhibitory Concentration (MIC)  | 43  |
| 3.8   | Biofilm Inhibition Assay   | 43  |
| 4     | Result   | 45  |
| 4.1   | Isolation and Identification of Bacteria   | 46  |
| 4.1.1 | Isolation and Identification of Lactic Acid Bacteria (LAB)   | 46  |
| 4.1.2 | Isolation and Identification of Pathogenic Bacteria from Burns<br>Infections                                     | 48  |
| 4.1.3 | Bacterial Identification and Antibiotic Susceptibility Test using<br>VITEK 2 Compact System                      | 49  |
| 4.2   | Antibiotic Activity Alone and in Combination with CFS of<br><i>Lactobacilli</i> Isolates                         | 51  |
| 4.2.1 | Antibiotic Sensitivity Test  | 51  |
| 4.3   | The <i>Lactobacill</i> Isolates were Auto-aggregated and Co-<br>aggregated with Burn Infection Isolated Pathogen | 56  |
| 4.4   | Minimum Inhibitory Concentration (MIC-90)  | 60  |
| 4.5   | Minimum Biofilm Inhibitory Concentrations (MBIC 50)  | 71  |
| 5     | Discussion   | 104 |
| 5.1   | Antibiotic Susceptibility Test of Bacterial Isolates   | 106 |
| 5.2   | The <i>Lactobacillus</i> strains Auto-aggregation and Co-aggregation with Isolated Pathogen                      | 111 |
| 5.3   | Minimum Inhibitory Concentration (MIC-90)  | 112 |
| 5.4   | Minimum Biofilm Inhibitory Concentrations (MBIC 50)  | 113 |
| 6     | Conclusions and Recommendations  |     |
| 6.1   | Conclusions  | 116 |
| 6.2   | Recommendations  | 118 |
|       | References   | 119 |
|       | Appendix   | 146 |

# List of Tables

| No.          | Heading   | Page |
|--------------|---|------|
| Table (3.1)  | Instruments and Tools Utilized in the Study   | 30   |
| Table (3.2)  | Types of Antibiotics  | 31   |
| Table (3.3)  | Culture Media Used in the Curent Study  | 32   |
| Table (3.4)  | Type of Chemical and Reagent  | 35   |
| Table (4.1)  | Biochemical Test for Identification Lactic Acid Bacteria  | 47   |
| Table (4.2)  | Numbers and Percentages of Bacterial Isolates from<br>Burns Patients  | 49   |
| Table (4.3)  | Zone of growth inhibition (mm) when antibiotic was<br>used alone and in combination with CFS of<br><i>Lactobacillus</i> spp. against <i>A. baumannii</i>  | 52   |
| Table (4.4)  | Zone of growth inhibition (mm) when antibiotic was<br>used alone and in combination with CFS of<br><i>Lactobacillus</i> spp. against <i>P. aeruginosa</i> | 53   |
| Table (4.5)  | Zone of growth inhibition (mm) when antibiotic was<br>used alone and in combination with CFS of<br><i>Lactobacillus</i> spp. against <i>K. pneumonia</i>  | 54   |
| Table (4.6)  | Zone of growth inhibition (mm) when antibiotic was<br>used alone and in combination with CFS of<br><i>Lactobacillus</i> spp. against <i>S. aureus</i>     | 55   |
| Table (4.7)  | The auto-aggregation percentages of the selected <i>Lactobacillus</i> and the isolated pathogenic bacteria  | 56   |
| Table (4.8)  | The co-aggregation percentages between the bacterial isolates and <i>Lactobacillus</i> strains  | 58   |
| Table (4.9)  | Antibacterial activity of <i>L. acidophilus</i> CFS against pathogenic bacterial isolates   | 62   |
| Table (4.10) | Antibacterial activity of <i>L. plantarum</i> spp. 1 CFS against pathogenic bacterial isolates  | 65   |
| Table (4.11) | Antibacterial activity of <i>L. plantarum</i> spp. 2 CFS against pathogenic bacterial isolates  | 68   |
| Table (4.12) | Antibacterial activity of <i>L. plantarum</i> spp.3 CFS against pathogenic bacterial isolates   | 70   |
| Table (4.13) | Anti-biofilm activity of <i>L. acidophilus</i> CFS against <i>A. baumannii</i>  | 73   |
| Table (4.14) | Anti-biofilm activity of <i>L. plantarum</i> spp. 1 CFS against <i>A. baumannii</i>   | 75   |
| Table (4.15) | Anti-biofilm activity of <i>L. plantarum</i> spp. 2 CFS against <i>A. baumannii</i>   | 77   |
| Table (4.16) | Anti-biofilm activity of <i>L. plantarum</i> spp. 3 CFS against <i>A. baumannii</i>   | 79   |
| Table (4.17) | Anti-biofilm activity of <i>L. acidophilus</i> CFS against <i>P. aeruginosa</i>   | 81   |
| Table (4.18) | Anti-biofilm activity of <i>L. plantarum</i> spp. 1 CFS against <i>P. aeruginosa</i>  | 83   |

| Table (4.19) | Anti-biofilm activity of <i>L. plantarum</i> spp. 2 CFS against <i>P. aeruginosa</i> | 85  |
|--------------|--|-----|
| Table (4.20) | Anti-biofilm activity of <i>L. plantarum</i> spp. 3 CFS against <i>P. aeruginosa</i> | 87  |
| Table (4.21) | Anti-biofilm activity of <i>L. acidophilus</i> CFS against <i>K. pneumonia</i>       | 89  |
| Table (4.22) | Anti-biofilm activity of <i>L. plantarum</i> spp. 1 CFS against <i>K. pneumonia</i>  | 91  |
| Table (4.23) | Anti-biofilm activity of <i>L. plantarum</i> spp. 2 CFS against <i>K. pneumonia</i>  | 93  |
| Table (4.24) | Anti-biofilm activity of <i>L. plantarum</i> spp. 3 CFS against <i>K. pneumonia</i>  | 95  |
| Table (4.25) | Anti-biofilm activity of <i>L. acidophilus</i> CFS against <i>S. aureus</i>          | 97  |
| Table (4.26) | Anti-biofilm activity of <i>L. plantarum</i> spp. 1 CFS against <i>S. aureus</i>     | 99  |
| Table (4.27) | Anti-biofilm activity of <i>L. plantarum</i> spp. 2 CFS against <i>S. aureus</i>     | 101 |
| Table (4.28) | Anti-biofilm activity of <i>L. plantarum</i> spp. 3 CFS against <i>S. aureus</i>     | 103 |

# List of Figures and Pictures

| Series        | Item  | Page |
|---------------|---|------|
| Figure 1      | Structure of the skin   | 10   |
| Figure 2      | Burn depth  | 12   |
| Figure 3      | Developing Antibiotic Resistance  | 23   |
| Fig (4.1)     | Lactobacillus plantarum on MRS agar   | 47   |
| Fig (4.2)     | Lactobacillus acidophilus on MRS agar   | 47   |
| Figure (4.3)  | Auto- aggregation of all isolates   | 57   |
| Figure (4.4)  | Co-aggregation of <i>Lactobacillus</i> spp. When mixed with pathogenic strains  | 59   |
| Figure (4.5)  | Antimicrobial activity of <i>L. acidophilus</i> spp. against isolated pathogens | 60   |
| Figure (4.6)  | Antimicrobial activity of <i>L. plantarum</i> spp 1 against isolated pathogens  | 63   |
| Figure (4.7)  | Antimicrobial activity of <i>L. plantarum</i> spp. 2 against isolated pathogens | 66   |
| Figure (4.8)  | Antimicrobial activity of <i>L plantarum</i> spp 3 against isolated pathogens   | 69   |
| Figure (4.9)  | Effect of CFS of <i>L. acidophilus</i> on <i>A. baumanni</i> biofilm            | 72   |
| Figure (4.10) | Effect of CFS of <i>L. plantarum</i> spp. 1 on <i>A. baumanni</i> biofilm       | 74   |
| Figure (4.11) | Effect of CFS of <i>L. plantarum</i> spp. 2 on <i>A. baumanni</i> biofilm       | 76   |
| Figure (4.12) | Effect of CFS of <i>L. plantarum</i> spp. 3 on <i>A. baumanni</i> biofilm       | 78   |
| Figure (4.13) | Effect of CFS of <i>L. acidophilus</i> on <i>P. aeruginosa</i> biofilm          | 80   |
| Figure (4.14) | Effect of CFS of <i>L. plantarum</i> spp. 1 on <i>P. aeruginosa</i> biofilm     | 82   |
| Figure (4.15) | Effect of CFS of <i>L. plantarum</i> spp. 2 on <i>P. aeruginosa</i> biofilm     | 84   |
| Figure (4.16) | Effect of CFS of <i>L. plantarum</i> spp. 3 on <i>P. aeruginosa</i> biofilm     | 86   |
| Figure (4.17) | Effect of CFS of <i>L. acidophilus</i> on <i>K. pneumoniae</i> biofilm          | 88   |
| Figure (4.18) | Effect of CFS of <i>L. plantarum</i> spp. 1 on <i>K. pneumoniae</i> biofilm     | 90   |
| Figure (4.19) | Effect of CFS of <i>L. plantarum</i> spp. 2 on <i>K. pneumoniae</i> biofilm     | 92   |
| Figure (4.20) | Effect of CFS of <i>L. plantarum</i> spp. 3 on <i>K. pneumoniae</i> biofilm     | 94   |
| Figure (4.21) | Effect of CFS of <i>L. acidophilus</i> on <i>S. aureus</i> biofilm              | 96   |
| Figure (4.22) | Effect of CFS of <i>L. plantarum</i> spp. 1 on <i>S. aureus</i> 98<br>biofilm   |      |
| Figure (4.23) | Effect of CFS of <i>L. plantarum</i> spp. 2 on <i>S. aureus</i> biofilm         | 100  |
| Figure (4.24) | Effect of CFS of L. plantarum spp. 3 on S. aureus                               | 102  |

| biofilm |  |
|---------|--|
|---------|--|

| Letter or Symbol | Meaning                                     |
|------------------|---|
| -                | Negative result / not able to growth        |
| +                | Positive result / able to growth            |
| μg               | Microgram                                   |
| μm               | Micrometre                                  |
| A                | Acid  |
| AK 30            | Amikacin in 30 Mcg                          |
| ALK              | Alkaline                                    |
| AMR              | Antimicrobial resistance                    |
| ANOVA            | Analysis of variance                        |
| AX 25            | Amoxcilin in 25 Mcg                         |
| AZM 15           | Azithromycin (15) Mcg                       |
| BHI              | Brain heart infusion                        |
| BHI              | Brain Heart Infusion Broth                  |
| CFS              | Cell Free Supernatant                       |
| CFU              | Colony-forming unit                         |
| CPS              | Capsular polysaccharide                     |
| CS 10            | Coliston sulphid in 10 Mcg                  |
| D.W.             | Distilled water                             |
| EPS              | Extracellular polysaccharides               |
| ESBL             | extended spectrum beta-lactamase            |
| FAO              | Food and Agriculture Organization of the    |
|                  | United Nations                              |
| H <sub>2</sub> S | Hydrogen Sulfide                            |
| Ib               | Pound                                       |
| ISAPP            | International Scientific Association For    |
|                  | Probiotics And Prebiotics                   |
| Kg               | Kilogram                                    |
| L 10             | Lincomycin in 10 Mcg                        |
| LAB              | Lactic Acid Bacteria                        |
| MBIC             | Minimum biofilm Inhibitory Concentration    |
| MDR              | Multidrug Resistance                        |
| ME 10            | Methicillin in 10 Mcg                       |
| Mg               | Milligram                                   |
| MIC              | Minimum Inhibitory Concentration            |
| Mm               | Millimeter                                  |
| MRAB             | multidrug-resistant Acinetobacter baumannii |
| MRS              | De man, Rogosa and Sharpe                   |
| MRSA             | methicillin-resistant Staphylococcus aureus |
| NA 10            | Naldixic acid in 10 Mcg                     |
| Nm               | Nanometer                                   |

# List of Abbreviations

| P 10   | Penicillin in 10 IU               |
|--------|-----------------------------------|
| PBS    | Phosphate buffer saline           |
| R      | Resistance                        |
| Rpm    | Reotation per minute              |
| S      | Sensitive                         |
| TCS    | two-component systems             |
| Tob 10 | Tobramycin in 10 Mcg              |
| TSI    | Triple Sugar Iron                 |
| VA 30  | Vancomycin in 30 Mcg              |
| VRE    | vancomycin-resistant Enterococcus |
| VRSA   | vancomycin-resistant S. aureus    |
| WELL   | Use CFS alone                     |
| WHO    | World Health Organization         |

# **CHAPTER ONE**

# INTRODUCTION

#### **1.1 INTRODUCTION**

The most large organ in human body is the skin, skin makes up around 15% of an adult human's entire body weight. It is made of Three main layers, including "from top to bottom" the epidermis with appendages, dermis and the hypodermis. These layers having their own specific functions; including (i) protection from external physical, chemical and biological factors, (ii) preventing excess water loss and (iii) thermoregulation in addition to being (iv) a sensory organ. The skin also protects the body from the entry of various microorganisms, including bacteria, viruses and fungi etc. The skin is lined with a mucous membranes. The body is easily susceptible to harm due to the exposure of the skin layers to burning or tearing (Sullivan *et al.*, 2022).

One of the most common injuries to the skin is burns, it's have a significant impact on the patients in many ways; physically, psychologically, and physiologically. Burns are still considered among the top of death causes and disability in the world (Ribeiro *et al.*, 2008). Microbial infections also considered as the main causes of morbidity and mortality increasing in patients burned-skin. These infections could be viral, fungal and bacterial infections, especially infections caused by multidrug-resistant strains (MDR). *Staphylococcus* spp, *beta-hemolytic Streptococcus* group A and *Enterococcus* spp. are distinguished as the most common Gram-positive bacteria involved in burn infections, While Gram-negative bacteria include *Pseudomonas* 

aeruginosa, Klebsiella spp, Stenotrophomonas spp., Enterobacter cloacae., Acinetobacter baumannii and Escherichia coli (Weber et al., 2004; Ronat et al., 2014).

These pathogenic bacteria have virulence factors which allow them to colonize, reproduce, produce enzymes/toxins and causing infection, most of these infections are resistance to various traditional antimicrobial agents (Casadevall and Pirofski, 2009; Ryding, 2021).

Antimicrobial resistance (AMR) occurs when microbes develop mechanisms to protect themselves from antimicrobial effects. Each year, the infections of AMR kills millions of people. Resistant microbes infections are more difficult to be treated. A higher doses of antimicrobial drugs, in this situation potentially more toxic medications will be enough to control such infection, these methods may also be more costly. Genetic mutation play an important role in bacterial resistance development or even as a result of acquiring resistance from one species to another. Antimicrobial resistance is increasing globally as a result of a random antibiotic prescription and dispensing in developing countries (Vega and Gore, 2014).

Bacterial cells are commonly found in nature either as varied communities embedded in a complex matrix, or as simple planktonic cells. Biofilms formation is the most important virulence factor of pathogenic bacteria which colonize onto a variety of biotic (tissues) and abiotic (devices) surfaces (Reg Bott, 2011; Jamal *et al.*, 2018). Bacteria form biofilm to protect themselves from the harmful environmental circumstances such osmotic stress, metal toxicity, and antibiotic exposure (Gebreyohannes *et al.*, 2019).

Pathogens that develop biofilms are linked to persistent infections in up to 80% of cases. About 90% of the biofilm mass is made up of proteins, DNA, and extracellular polysaccharides (EPS). In addition to cell stability and mediating surface adhesion, EPS also serves as a scaffold for the attachment of cells, enzymes, and antibiotics (Flemming and Wingender, 2010; Beloin, 2014).

Antibiotic-resistant diseases are growing widespread in the whole world, and this means that treatments for these diseases are becoming rare (Cerceo *et al.*, 2016). It is anticipated that will be no effective antibiotic available to treat infections by 2050 if no new antibiotics are manufactured or discovered (Rolain *et al.*, 2016).

The direct administration of probiotics to burn patients is a unique strategy that avoids the drawbacks of current antibiotic therapy (Argenta *et al.*, 2016). According with a current definition, "Probiotics are live microorganisms that, when provided in suitable proportions, confer a health effect on the host". This definition of probiotics was created and supported by the "Food and Agriculture Organization" of the United Nations (FAO), "The World Health Organization" (WHO), and "the International Scientific Association for Probiotics and Prebiotics" (ISAPP) (Hill *et al.*, 2014). Probiotic

therapy has been shown in animal models and patients to reduce infections of the middle ear, bladder, gut, and urogenital tract, in addition to its applications in the lay press and food sector (Patra *et al.*, 2022).

Cow milk is a light liquid made by a cow's mammary glands. It is an infant mammal's principal source of nutrition until they have the ability to digest the other foods. It also includes a variety of other nutrients, like lactose and protein (Van *et al.*, 2011). Lactic acid bacteria (LAB) grow in milk, which is one of their natural environments (Delavenne *et al.*, 2012). Lactic acid bacteria (LAB) are found in milk and milk products naturally (Chen *et al.*, 2005).

The bacteria that produced lactic acid are frequently used as probiotics because of their capacity to outcompete infections. In addition, they regulating the immune response, inhibiting neutrophil and macrophage death and increasing phagocytic activity (De LeBlanc Ade et al., 2010; Ramos et al., 2010). Lactobacillus bacteria are the most common probiotics including; "Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosusand Lactobacillus delbrueckii subsp. Bulgaricus" in addition to Bifidobacterium genera "e.g., Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium animalis subsp. Lactis". Also, some bacterial strains from other species were reported to show a probiotic potential "e.g., Lactococcus lactis, Propionibacterium acidilactici, Leuconostoc mesenteroides, Bacillus subtilis, Enterococcus faecium, Escherichia coli, and

#### CHAPTER ONE

Streptococcus thermophiles" and some certain yeasts "e.g., Saccharomyces boulardii" (Fijan, 2014).

#### **1.2.** Objectives of the Study

1-Isolation and identification (using VITEK 2 compact system) of the followings;

a- Lactic acid bacteria (LAB) are present in milk samples collected from healthy lactating cows.

b- The most bacterial contaminants from the clinical samples collected from burns infections cases, such as *Staphylococcus* spp., *Pseudomonas aeruginosa*, *Acenitobacter baumannii* and *klebsiella pneumonia*.

2- Performing auto-aggregation of LAB and their co-aggregation with the clinical isolates of bacterial contaminants.

3- Evaluation of antimicrobial activity of Cell Free Supernatants (CFS) of LAB against burn contaminant isolates using agar well diffusion assay.

4- Evaluation of antimicrobial combinations of LAB CFS with some antibiotics against burn bacterial contaminant using a modified disk diffusion assay.

5- Determination of "Minimum Inhibitory Concentration" (MIC) and "Minimum Biofilm Inhibitory Concentration" (MBIC) CFS extracted from isolated *Lactobacilli* spp. against biofilm formation by above mentioned bacterial contaminants.